Health Care [ 3/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 26 | -1.17 Decreased by -40.96% | -1.13 Decreased by -3.54% |
| Feb 26, 26 | -1.31 Decreased by -55.95% | -1.19 Decreased by -10.08% |
| Nov 3, 25 | -1.15 Decreased by -41.98% | -1.15 |
| Aug 11, 25 | -1.07 Decreased by -42.67% | -0.99 Decreased by -8.08% |
| Jun 4, 25 | -0.83 Decreased by -33.87% | -0.90 Increased by +7.49% |
| Feb 26, 25 | -0.84 Decreased by -31.25% | -0.84 Decreased by -0.10% |
| Nov 6, 24 | -0.81 Decreased by -10.96% | -0.81 |
| Aug 8, 24 | -0.75 Decreased by -4.17% | -0.70 Decreased by -7.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by -100.00% | -102.30 M Decreased by -57.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -105.26 M Decreased by -60.25% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -90.90 M Decreased by -44.76% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -84.71 M Decreased by -46.24% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 7.50 M Increased by +N/A% | -65.05 M Decreased by -35.71% | Decreased by -867.29% Decreased by N/A% |
| Dec 31, 24 | 2.52 M Decreased by -53.23% | -65.69 M Decreased by -46.81% | Decreased by -2.61 K% Decreased by -213.92% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -62.79 M Decreased by -29.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -57.92 M Decreased by -22.05% | Decreased by N/A% Decreased by N/A% |